Donald Trump announces phased tariffs on imported generic drugs from 2028

The two-year tariff-free window could prompt overseas manufacturers and US importers to reassess production, investment and sourcing before higher duties take effect. President Donald Trump has announced that generic drugs imported into the US will remain subject to a zero tariff for two years from 1 August 2026, followed by a 100% tariff for one year and a 200% tariff thereafter. If formalised, the timetable could materially change the economics of supplying the US generics market and increase pressure on manufacturers to establish domestic production.

Field	Content
Alert Type	Industry Update
Topic	Trade policy and pharmaceutical manufacturing
Organisation(s)	US administration; President Donald Trump
Affected Stakeholders	Overseas generic-drug manufacturers, US pharmaceutical importers and companies reliant on imported generic products or ingredients
Geography	US
What Happened	Trump announced that imported generic drugs would retain a zero tariff for two years from 1 August 2026. The announced rate would then rise to 100% for one year and 200% thereafter, with the stated aim of encouraging generic-drug manufacturers to build production capacity in the US. The announcement did not itself provide the formal tariff classifications, exemptions or implementation mechanism.
Why It Matters	The proposed rates could substantially alter manufacturing and sourcing decisions for companies supplying generic medicines to the US. The two-year transition gives affected businesses time to evaluate domestic investment, but the commercial consequences will depend on the final scope and rules.
Supporting Context	An April 2026 presidential proclamation imposed tariffs on certain patented pharmaceutical products but stated that generic pharmaceuticals, associated ingredients and biosimilars would not be subject to Section 232 tariffs at that time. It also required the Department of Commerce to report within one year on circumstances that might support further action on generic imports.
Who Is Most Affected	Foreign manufacturers supplying generic medicines to the US face the clearest potential exposure. US importers may need to review suppliers and costs, while domestic manufacturers could gain a stronger incentive to expand capacity.
Industry Impact	If implemented as announced, the policy could accelerate US manufacturing investment and encourage supply-chain restructuring. Its effect on medicine costs, competition and availability would depend on whether manufacturers can establish sufficient domestic capacity and on any exemptions included in the formal rules.
Key Takeaway	Generic-drug manufacturers have been given an announced two-year planning window, but formal implementation details will determine which products and companies are ultimately affected.
What to Watch	A presidential proclamation, Federal Register notice or Department of Commerce guidance confirming the legal basis, covered tariff codes, treatment of active pharmaceutical ingredients and biosimilars, exemptions and criteria for qualifying US investment.
Primary Source	President Donald Trump’s Truth Social announcement
Relevant Date	21 July 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com